Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients with Localized Triple-Negative Breast Cancer (TNBC) with Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
MD Anderson Study Status
Bevacizumab, Everolimus, Pegylated Liposomal Doxorubicin Hydrochloride
This phase II trial studies how well pegylated liposomal doxorubicin, bevacizumab, and everolimus work in treating patients with triple-negative breast cancer with tumors predicted insensitive to standard chemotherapy. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin, work in different ways to stop the growth of tumor cells by stopping them from dividing.Monoclonal antibodies, such as bevacizumab binds to VEGF receptor, thus halting vessel growth in the tumor and thereby causing cell death. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pegylated liposomal doxorubicin together with bevacizumab and everolimus may kill more tumor cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Breast Medical Oncology
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.